Last edition
News about "pivotal Phase 3 development"
Vir Biotechnology's VIR-5500 Receives FDA Fast Track Designation for Prostate Cancer
Vir Biotechnology and Astellas are advancing VIR-5500 for late-line metastatic castration-resistant prostate cancer following encouraging preliminary Phase 1 findings.
Pivotal Phase 3 Development | 12/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members